Table 2.
Technique | Method | MSN Role | Target Biomarker | Key Performances | Reference |
---|---|---|---|---|---|
Potentiometry | Commercial glucometer | Release of glucose upon target cDNA hybridization | miRNA-21 | 50 pM–5 nM 1 19 pM 2 |
[84] |
Release of glucose upon target binding to antibody | CYFRA 21-1 | 1.3–160 ng/mL 1 | [85] | ||
Open circuit voltage | Release of [Fe(CN)6]3− upon target cDNA hybridization | miRNA-21 | 10 aM–1 pM 1 | [86] | |
Chrono-potentiometry | MIP performance improvement | Sarcosine | 10 nM–10 μM 1 7.8 Nm 2 |
[87] | |
Amperometry | Chrono-amperometry | Lactate oxidase immobilization | Lactic acid | 40–500 μM 1 | [88] |
Voltammetry | Cyclic voltammetry | Antibody immobilization with AgNP for electron transfer improvement | PSA | 50 pg/mL–50 ng/mL 1 15 pg/mL 2 |
[89] |
Differential pulse voltammetry | Release of glucose from target-bound MSNs | CA 19-9 | 0.01–100 U/mL 1 0.0005 U/mL 2 |
[90] | |
Dual-labeled MSNs with AuNRs and HRP for signal enhancement | CEA | 0.1–5 pg/mL 1 5.25 fg/mL 2 |
[91] | ||
Sandwich-type immunoassay with MB@MSNs for signal enhancement | HPV16 E6 oncoprotein | 50 fg/mL–4 ng/mL 1 | [92] | ||
Amino-MSNs in composite with Amino-rGO and IL for signal enhancement | Lysozyme | 20 fM–50 nM 1 | [93] | ||
SNA-loaded MSNs for improved capture of target | MCF-7 cancer cells | 1−1.0 × 107 cells/mL 1 4 cells/mL 2 |
[94] | ||
Sandwich-type immunoassay with MMSN@AuNP-Ab2 for signal enhancement | CYFRA 21-1 | 0.01–1.0 pg/mL 1 2 fg/mL 2 |
[95] | ||
Sandwich-type immunoassay with thionine-loaded MSNs for signal enhancement | SCCA | 0.01–120 ng/mL 1 0.33 pg/mL 2 |
[96] | ||
Square wave voltammetry | Sandwich-type immunoassay with MB-loaded MSNs for signal production by controlled MB release | PSA | 10 fg/mL–100 ng/mL 1 1.25 fg/mL 2 |
[97] | |
Release of MB from programmed target-enabled CHA for HCR signal amplification | miRNA-21 | 0.1 fM–5 pM 1 | [98] | ||
Sensitivity improvement by MSNs/PtNPs | CD133 | 5–20 cells/5 μL 1 | [99] | ||
Square wave anodic/cathodic stripping voltammetry | Nanocomposites for signal development and enhancement: PbS-QD@MSNs, CdTe-QD@MSNs, and AuNPs@MSNs | HE4, CA-125, and AFP |
HE4: 0.02–20 pM 1; LOD 5.07 pM CA-125: 0.45–450 IU/L 1; LOD 3.1 IU/L AFP: 0.1–500 ng/L 1; LOD 2.44 pg/L |
[100] | |
Impedimetry | Electrochemical impedance spectroscopy | Amino-MSNs in composite with Amino-rGO and IL for signal enhancement | Lysozyme | 10 fM–200 nM 1 | [93] |
Photoelectrochemical method | Chrono-amperometry | CD@MSB for improved sensitivity | Glutathione | 34.9 nM 2 | [101] |
1 Linear range. 2 LOD. Abbreviations: MIP—molecularly imprinted polymer; cDNA—complementary DNA; Ag NPs—silver nanoparticles; AuNRs—gold nanorods; HRP—horseradish peroxidase; MB—methylene blue; HPV16—human papillomavirus 16; rGO—reduced graphene oxide; IL—ionic liquid; SNA—sambucus nigra agglutinin; MMSN—magnetic MSN; AuNPs—gold nanoparticles; CHA—catalytic hairpin assembly; HCR—hybridization chain reaction; PtNPs—platinum nanoparticles; PbS QDs—lead sulfide quantum dots; CdTe QDs—cadmium telluride quantum dots; and CDs—carbon dots.